Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Shares of Arcutis Biotherapeutics are down 0.04% at $25.15. The company is worth $3.16B, number 2441 out of 3132 on our list.
Over the past 52 weeks it has traded between $19.30 and $31.77, so it sits 20.8% below the top of that range. Holders are ahead 27.3% over twelve months, but down 9.1% across the last three months.
On the chart it has slipped under both the 50-day ($25.65) and 200-day ($25.19) moving averages; RSI is 47, and the last 30 sessions moved at roughly 51% annualized volatility.
For the quarter ended Jun 2026 it reported $129.86M in revenue, up 59.3% from a year earlier, with $15.01M of net profit (a -4.3% margin).
Valuation works out to 114.3 times trailing earnings.
5 analysts follow the stock and the average call is "buy". The mean target, $37.00, sits 47.1% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 3131 U.S. stocks BeStock covers.
Trading closer to its 52-week high than most peers scores higher.
5 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
ARQT is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $37.00, 47.1% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $20.75, so shares trade 21.2% above that estimate.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -1.5% | Bearish |
| Price vs 50-day average | -1.9% | Bearish |
| Price vs 200-day average | -0.2% | Bearish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 46.8 | Bearish |
| MACD (12,26,9) | 0.17 | Bearish |
| Bollinger band position | 43% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 6, 2026 6:40 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,131 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$25.15 is the latest print for ARQT, a move of -0.04% against yesterday's close of $25.16. Today's low and high so far: $24.69 and $25.39.
Equity value comes to $3.16B at the current price. By that measure it is number 2441 of the 3132 names in our coverage.
Buyers pay 114.3 times the last twelve months of profit (EPS $-0.13).
The year's floor is $19.30 and the ceiling $31.77. Shares are 20.8% away from that ceiling.
Our data shows no dividend paid by Arcutis Biotherapeutics over the trailing twelve months.
Of 5 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $37.00, with the most cautious at $34.00 and the most optimistic at $40.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on ARQT.